AI reads your Heart's future: new test spots cancer drug danger

NCT ID NCT07515859

Completed Knowledge-focused Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at over 31,000 cancer patients to see if an AI-enhanced electrocardiogram (ECG) could predict heart damage caused by chemotherapy. Researchers analyzed existing ECGs taken before treatment to see if the AI could identify those at risk. The goal is to develop a simple, non-invasive tool to help doctors personalize cancer therapy and prevent heart failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple, low-cost ECG test to identify patients at high risk of heart damage before starting cancer therapy.
What could go wrong: This is a retrospective study, not a controlled trial, so results may not apply to all patients. The AI tool needs further validation in prospective studies before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER THERAPY-RELATED CARDIAC DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cardiotoxicity heart failure left ventricular failure Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER THERAPY-RELATED CARDIAC DYSFUNCTION HEART FAILURE LEFT VENTRICULAR DYSFUNCTION

AI reads your Heart's future: new test spots cancer drug danger

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions